India Telmisartan Market to grow at a steady rate During the Forecast Period

Growing prevalence of hypertension is expected to drive the growth of India Telmisartan market.

According to TechSci Research report, “India Telmisartan Market By Indication (Hypertension, Cardiac Arrest, Stroke, Others), By Composition (Single, Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India telmisartan market is expected to grow at a steady rate during the forecast period for the treatment of essential hypertension. In addition to this, rising demand for developing antihypertensive drugs is expected to fuel the market growth through FY2026. However, side-effects associated with drug consumption such as upper respiratory tract infections, diarrhea, back pain, kidney problems, low blood pressure, and angioedema can restrict the market growth over the next few years. Moreover, in certain cases use of this drug in pregnancy may harm the baby. This can further reduce the usage and application of the drug thereby hindering the market growth during the forecast period.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on“ India Telmisartan Market “

https://www.techsciresearch.com/report/india-telmisartan-market/5150.html

The India telmisartan market is segmented based on indication, composition, form, route of administration, source, distribution channel, end user, company, and region. Based on indication, the market can be fragmented into hypertension, cardiac arrest, stroke, others. The hypertension segment is expected to dominate the market in the forthcoming years on account of rising prevalence of high blood pressure among the population. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until 2017 as most of the leading companies focus on in house production. Contract manufacturing organizations segment is expected to witness significant growth in the market as it saves cost and maximize profits. Besides, high growth in number of contract manufacturers is further contributing to its fast growing CAGR. In terms of form, the market is split into tablet, capsule, injection, others. Among them, the capsule segment is anticipated to dominate the market in the next 5 years which is attributable to the fact that they are easy to use and readily available. Also, the tablet segment is expected to register high growth during then forecast years on account of their properties such as high stability of tablets and longer shelf life.

Astellas Pharma India Pvt. Ltd., Boehringer Ingelheim India Pvt. Ltd., Novartis India Ltd., Venus Remedies Ltd., Candomed Pharmaceuticals India Pvt. Ltd, Torrent Pharmaceuticals Ltd., Cipla Limited (Exelan Pharmaceuticals), Lupin Laboratories Ltd., Mylan Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Astellas Pharma India Pvt. Ltd. and others are some of the leading players operating in India telmisartan market. Companies operating in the market are using Go-To-Market strategies such as product launches, mergers, and collaborations to boost their share and increase their geographic reach. For instance, In 2017, Zydus Cadila which is one of the leading pharmaceutical company in the market received permission to sell its version of temisartan and hydrocholothiazide tablets and the drug was brought into the market in three different dosages, which contributed in strengthening their market share.

 Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5150

Customers can also request for 10% free customization on this report.

“India Telmisartan market is expected to witness growth during the forecast period as it is used to treat patients with high blood pressure and thereby aids to prevent strokes, heart attacks, and other related conditions in an individual. Telmisartan medication is also very effective in treating diabetic kidney disease. This is further expected to create lucrative opportunities for the market growth of India Telmisartan market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.

“India Telmisartan Market By Indication (Hypertension, Cardiac Arrest, Stroke, Others), By Composition (Single, Combinational), By Form (Tablet, Capsule, Injection, Others), By Route of Administration (Oral v/s Intravenous), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India telmisartan market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India telmisartan market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]